Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

GNPS - Drug metabolism - Bacterial synthetic community

ABSTRACT: Bacterial culture with drugs acquired on Q Exactive with chromatographic separation on a Phenomenex polar C18 column (Kinetex 2.6 um, 150 x 2.1 mm). Reversed-phase, ESI positive.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Bacteria (ncbitaxon:2)

SUBMITTER: Pieter C. Dorrestein

PROVIDER: MSV000095331 | GNPS | Sun Jul 14 16:47:00 BST 2024

REPOSITORIES: GNPS

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Drug metabolism - Bacterial synthetic community

Project description:Bacterial culture with drugs acquired on Q Exactive with chromatographic separation on a Phenomenex polar C18 column (Kinetex 2.6 um, 150 x 2.1 mm). Reversed-phase, ESI positive.

2024-07-14 | MSV000095331 | MassIVE

GNPS - Drug metabolism by gut community

Project description:Bacterial community culture with drugs acquired on Exploris 240 with chromatographic separation on a Phenomenex polar C18 column (Kinetex 2.6 um, 100 x 2.1 mm). Reversed-phase, ESI positive.

2024-12-04 | MSV000096589 | GNPS

Spatial transcriptome uncovers rich coordination of metabolism and signaling in bacterial community (data 2)

Project description:Spatial transcriptome uncovers rich coordination of metabolism and signaling in bacterial community (data 2)

2023-03-01 | GSE213531 | GEO

185-member bacterial synthetic community

Project description:A single bacterial genus maintains root development in a complex microbiome

| PRJNA543313 | ENA

Deciphering Differential Gut Bacterial Drug Metabolism with Activity-Based Protein Profiling

Project description:Gut bacterial β-glucuronidases (GUS) promote the toxic side effects of therapeutics by reactivating drugs from their inactive glucuronide conjugates. It is increasingly clear that the interindividual variability of bacterial GUS-producing species in the gut microbiota contributes to differential drug responses. Indeed, the anticancer drug irinotecan exhibits variable clinical toxicity outcomes that have been linked to interindividual differences in the composition of the gut microbiota. However, identification of the specific GUS enzymes responsible for drug metabolism in the context of the complexity of the human fecal microbiota has not been achieved. Here we pinpoint the specific bacterial GUS enzymes that reactivate SN-38, the active metabolite of irinotecan, from complex human fecal microbiota samples with activity-based protein profiling (ABPP). We identify and quantify gut bacterial GUS enzymes from human feces with ABPP-enabled proteomics and then integrate this information with ex vivo kinetics to reveal the specific GUS enzymes responsible for the reactivation of SN-38. The same ABPP approach also reveals the molecular basis for differential gut bacterial GUS inhibition between human fecal samples. Taken together, this work provides an unprecedented pipeline to identify the specific bacterial GUS enzymes responsible for drug-induced GI toxicity from the complexity of human feces, which may serve as highly precise biomarkers of clinical outcomes for irinotecan and other therapeutics.

2019-12-03 | PXD014864 | Pride

20231123_ChemProp2_Non-targeted Metabolomics of Xenobiotic Biotransformations using synthetic gut bacterial community

Project description:ChemProp2 Dataset: Investigating potential biotransformations with a panel of 45 Drugs on Synthetic Community (Com20) to elucidate Drug-Microbiome-Host Dynamics

2023-12-05 | MSV000093571 | MassIVE

Bacterial Community

Project description:Bacterial Community Metagenome

| PRJNA783784 | ENA

20240530_ChemProp2_Non-targeted Metabolomics of Xenobiotic Biotransformations using synthetic gut bacterial community

Project description:ChemProp2 Dataset: Investigating potential biotransformations with a panel of 12 Drugs on Synthetic Community (Com20) for 9 timepoints (t0 - t8) to elucidate Drug-Microbiome-Host Dynamics

2024-05-30 | MSV000094899 | MassIVE

Bacterial community

Project description:Bacterial community Raw sequence reads

| PRJNA589116 | ENA

bacterial community

Project description:bacterial community Raw sequence reads

| PRJNA1013744 | ENA